{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T04:53:25Z","timestamp":1795064005855,"version":"4.10.2"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T00:00:00Z","timestamp":1642723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1245\/s10434-021-11251-z","type":"journal-article","created":{"date-parts":[[2022,1,21]],"date-time":"2022-01-21T19:59:51Z","timestamp":1642795191000},"page":"2854-2866","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Is There a Relationship Between TILs and Regression in Melanoma?"],"prefix":"10.1245","volume":"29","author":[{"given":"Steven","family":"Morrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith","family":"Elenwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Vetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley P.","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Kashani-Sabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Pockaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi E.","family":"Kosiorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L.","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Mozzillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Schlomo","family":"Schneebaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Sentinel Lymph Node Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"11251_CR1","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1093\/jnci\/81.24.1893","volume":"81","author":"WH Clark Jr","year":"1989","unstructured":"Clark WH Jr, Elder DE, Guerry DT, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81:1893\u2013904.","journal-title":"J Natl Cancer Inst."},{"key":"11251_CR2","first-page":"4155","volume":"17","author":"M Antohe","year":"2019","unstructured":"Antohe M, Nedelcu RI, Nichita L, et al. Tumor-infiltrating lymphocytes: the regulator of melanoma evolution. Oncol Lett. 2019;17:4155\u201361.","journal-title":"Oncol Lett."},{"issue":"6","key":"11251_CR3","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/labinvest.2017.8","volume":"97","author":"PP Aung","year":"2017","unstructured":"Aung PP, Nagarajan P, Prieto VG. Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance. Lab Invest. 2017;97(6):657\u201368.","journal-title":"Lab Invest."},{"key":"11251_CR4","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jss.2021.05.008","volume":"267","author":"A Zaladonis","year":"2021","unstructured":"Zaladonis A, Farma J, Hill M, et al. A retrospective, observational analysis of tumor-infiltrating lymphocytes and tumor regression in melanoma. J Surg Res. 2021;267:203\u20138.","journal-title":"J Surg Res."},{"key":"11251_CR5","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","volume":"30","author":"F Azimi","year":"2012","unstructured":"Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30:2678\u201383.","journal-title":"J Clin Oncol."},{"key":"11251_CR6","unstructured":"Morrison S HG, Elenwa F, Vetto J, Fowler G, Leong SP, Kashani-Sabet M, et al. Is the presence of tumor-infiltrating lymphocytes prognostic in melanoma patients? International conference on surgical cancer care society of surgical oncology. 2021."},{"key":"11251_CR7","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ejca.2009.05.034","volume":"45","author":"M Mandal\u00e0","year":"2009","unstructured":"Mandal\u00e0 M, Imberti GL, Piazzalunga D, et al. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database. Eur J Cancer. 2009;45:2537\u201345.","journal-title":"Eur J Cancer."},{"key":"11251_CR8","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5","volume":"77","author":"CG Clemente","year":"1996","unstructured":"Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor-infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 1996;77:1303\u201310.","journal-title":"Cancer."},{"key":"11251_CR9","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1200\/JCO.2013.51.3002","volume":"31","author":"NE Thomas","year":"2013","unstructured":"Thomas NE, Busam KJ, From L, et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment, and melanoma study. J Clin Oncol. 2013;31:4252\u20139.","journal-title":"J Clin Oncol."},{"key":"11251_CR10","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1200\/JCO.2006.08.9755","volume":"25","author":"RC Taylor","year":"2007","unstructured":"Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol. 2007;25:869\u201375.","journal-title":"J Clin Oncol."},{"key":"11251_CR11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/000313481107700219","volume":"77","author":"AL Burton","year":"2011","unstructured":"Burton AL, Roach BA, Mays MP, et al. Prognostic significance of tumor-infiltrating lymphocytes in melanoma. Am Surg. 2011;77:188\u201392.","journal-title":"Am Surg."},{"key":"11251_CR12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/(SICI)1097-0142(19960801)78:3<427::AID-CNCR8>3.0.CO;2-G","volume":"78","author":"RL Barnhill","year":"1996","unstructured":"Barnhill RL, Fine JA, Roush GC, Berwick M. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer. 1996;78:427\u201332.","journal-title":"Cancer."},{"key":"11251_CR13","doi-asserted-by":"crossref","first-page":"e0148160","DOI":"10.1371\/journal.pone.0148160","volume":"11","author":"JP Duprat","year":"2016","unstructured":"Duprat JP, Brechtbulh ER, Costa de Sa B, et al. Absence of tumor-infiltrating lymphocyte is a reproducible predictive factor for sentinel lymph node metastasis: a multicenter database study by the Brazilian Melanoma Group. PLoS One. 2016;11:e0148160.","journal-title":"PLoS One."},{"key":"11251_CR14","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jaad.2018.02.066","volume":"79","author":"AJ Sinnamon","year":"2018","unstructured":"Sinnamon AJ, Sharon CE, Song Y, et al. The prognostic significance of tumor-infiltrating lymphocytes for primary melanoma varies by sex. J Am Acad Dermatol. 2018;79:245\u201351.","journal-title":"J Am Acad Dermatol."},{"key":"11251_CR15","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/cncr.22295","volume":"107","author":"LL Kruper","year":"2006","unstructured":"Kruper LL, Spitz FR, Czerniecki BJ, et al. Predicting sentinel node status in AJCC stage I\/II primary cutaneous melanoma. Cancer. 2006;107:2436\u201345.","journal-title":"Cancer."},{"key":"11251_CR16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1590\/abd1806-4841.20197414","volume":"94","author":"FMD Santos","year":"2019","unstructured":"Santos FMD, Silva FCD, Pedron J, Furian RD, Fortes C, Bonamigo RR. Association between tumor-infiltrating lymphocytes and sentinel lymph node positivity in thin melanoma. An Bras Dermatol. 2019;94:47\u201351.","journal-title":"An Bras Dermatol."},{"key":"11251_CR17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1001\/jamadermatol.2020.5032","volume":"157","author":"MA El Sharouni","year":"2021","unstructured":"El Sharouni MA, Aivazian K, Witkamp AJ, et al. Association of histologic regression with a favorable outcome in patients with stage 1 and stage 2 cutaneous melanoma. JAMA Dermatol. 2021;157:166\u201373.","journal-title":"JAMA Dermatol."},{"key":"11251_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2021.05.010","author":"S Subramanian","year":"2021","unstructured":"Subramanian S, Han G, Olson N, et al. Regression is significantly associated with outcomes for patients with melanoma. Surgery. 2021. https:\/\/doi.org\/10.1016\/j.surg.2021.05.010.","journal-title":"Surgery."},{"key":"11251_CR19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ijc.1491","volume":"94","author":"FH Saleh","year":"2001","unstructured":"Saleh FH, Crotty KA, Hersey P, Menzies SW. Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-A\/MART-1. Int J Cancer. 2001;94:551\u20137.","journal-title":"Int J Cancer."},{"key":"11251_CR20","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1038\/modpathol.2012.43","volume":"25","author":"MW Ma","year":"2012","unstructured":"Ma MW, Medicherla RC, Qian M, et al. Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node. Mod Pathol. 2012;25:1000\u201310.","journal-title":"Mod Pathol."},{"key":"11251_CR21","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1001\/jamadermatol.2013.9856","volume":"150","author":"R Botella-Estrada","year":"2014","unstructured":"Botella-Estrada R, Traves V, Requena C, Guillen-Barona C, Nagore E. Correlation of histologic regression in primary melanoma with sentinel node status. JAMA Dermatol. 2014;150:828\u201335.","journal-title":"JAMA Dermatol."},{"key":"11251_CR22","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1177\/000313481107700819","volume":"77","author":"AL Burton","year":"2011","unstructured":"Burton AL, Gilbert J, Farmer RW, et al. Regression does not predict nodal metastasis or survival in patients with cutaneous melanoma. Am Surg. 2011;77:1009\u201313.","journal-title":"Am Surg."},{"key":"11251_CR23","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.12659\/MSM.905862","volume":"24","author":"AF Letca","year":"2018","unstructured":"Letca AF, Ungureanu L, Senila SC, et al. Regression and sentinel lymph node status in melanoma progression. Med Sci Monit. 2018;24:1359\u201365.","journal-title":"Med Sci Monit."},{"key":"11251_CR24","first-page":"99","volume":"143","author":"RL Barnhill","year":"1993","unstructured":"Barnhill RL, Levy MA. Regressing thin cutaneous malignant melanomas (\u22641.0 mm) are associated with angiogenesis. Am J Pathol. 1993;143:99\u2013104.","journal-title":"Am J Pathol."},{"key":"11251_CR25","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1002\/1097-0142(197811)42:5<2282::AID-CNCR2820420528>3.0.CO;2-V","volume":"42","author":"MA Gromet","year":"1978","unstructured":"Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma: a distinctive lesion with metastatic potential. Cancer. 1978;42:2282\u201392.","journal-title":"Cancer."},{"key":"11251_CR26","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/PAS.0000000000000848","volume":"41","author":"G Saldanha","year":"2017","unstructured":"Saldanha G, Flatman K, Teo KW, Bamford M. A novel numerical scoring system for melanoma tumor-infiltrating lymphocytes has better prognostic value than standard scoring. Am J Surg Pathol. 2017;41:906\u201314.","journal-title":"Am J Surg Pathol."},{"key":"11251_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2018.03.053","volume":"80","author":"LJ Gardner","year":"2019","unstructured":"Gardner LJ, Strunck JL, Wu YP, Grossman D. Current controversies in early-stage melanoma: questions on incidence, screening, and histologic regression. J Am Acad Dermatol. 2019;80:1\u201312.","journal-title":"J Am Acad Dermatol."},{"key":"11251_CR28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pathol.2015.12.006","volume":"48","author":"N Lee","year":"2016","unstructured":"Lee N, Zakka LR, Mihm MC Jr, Schatton T. Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology. 2016;48:177\u201387.","journal-title":"Pathology."},{"key":"11251_CR29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/CMR.0b013e32835e5880","volume":"23","author":"TE Grotz","year":"2013","unstructured":"Grotz TE, Vaince F, Hieken TJ. Tumor-infiltrating lymphocyte response in cutaneous melanoma in the elderly predicts clinical outcomes. Melanoma Res. 2013;23:132\u20137.","journal-title":"Melanoma Res."},{"key":"11251_CR30","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/978-3-319-40618-3_47","volume-title":"AJCC cancer staging manual","author":"J Gershenwald","year":"2017","unstructured":"Gershenwald J, et al. Melanoma of the skin. In: MBES Amin, F Greene, DR Byrd, RK Brookland, MK Washington, JE Gershenwald, et al., editors. AJCC cancer staging manual. Switzerland: Springer; 2017. p. 563\u201385."},{"key":"11251_CR31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.6004\/jnccn.2019.0018","volume":"17","author":"DG Coit","year":"2019","unstructured":"Coit DG, Thompson JA, Albertini MR, et al. Cutaneous melanoma, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:367\u2013402.","journal-title":"J Natl Compr Canc Netw."},{"key":"11251_CR32","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1245\/s10434-017-6267-7","volume":"25","author":"SL Wong","year":"2018","unstructured":"Wong SL, Faries MB, Kennedy EB, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: American Society of Clinical Oncology and Society of Surgical Oncology clinical practice guideline update. Ann Surg Oncol. 2018;25:356\u201377.","journal-title":"Ann Surg Oncol."},{"key":"11251_CR33","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/archsurg.1992.01420040034005","volume":"127","author":"DL Morton","year":"1992","unstructured":"Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early-stage melanoma. Arch Surg. 1992;127:392\u20139.","journal-title":"Arch Surg."},{"key":"11251_CR34","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1365-2559.1990.tb00757.x","volume":"17","author":"K Blessing","year":"1990","unstructured":"Blessing K, McLaren KM, McLean A, Davidson P. Thin malignant melanomas (less than 1.5 mm) with metastasis: a histological study and survival analysis. Histopathology. 1990;17:389\u201395.","journal-title":"Histopathology."},{"key":"11251_CR35","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/bjd.12586","volume":"169","author":"S Ribero","year":"2013","unstructured":"Ribero S, Osella-Abate S, Sanlorenzo M, et al. Favourable prognostic role of regression of primary melanoma in AJCC stage I\u2013II patients. Br J Dermatol. 2013;169:1240\u20135.","journal-title":"Br J Dermatol."},{"key":"11251_CR36","doi-asserted-by":"crossref","first-page":"524700","DOI":"10.3389\/fonc.2020.524700","volume":"10","author":"Y Nakamura","year":"2020","unstructured":"Nakamura Y, Zhenjie Z, Oya K, et al. Poor lymphocyte infiltration to primary tumors in acral lentiginous melanoma and mucosal melanoma compared to cutaneous melanoma. Front Oncol. 2020;10:524700.","journal-title":"Front Oncol."},{"key":"11251_CR37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00000658-198808000-00004","volume":"208","author":"CL Slingluff Jr","year":"1988","unstructured":"Slingluff CL Jr, Vollmer RT, Reintgen DS, Seigler HF. Lethal \u201cthin\u201d malignant melanoma: identifying patients at risk. Ann Surg. 1988;208:150\u201361.","journal-title":"Ann Surg."},{"key":"11251_CR38","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1245\/s10434-007-9675-2","volume":"15","author":"KT Morris","year":"2008","unstructured":"Morris KT, Busam KJ, Bero S, Patel A, Brady MS. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol. 2008;15:316\u201322.","journal-title":"Ann Surg Oncol."},{"key":"11251_CR39","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1200\/JCO.1998.16.6.2253","volume":"16","author":"JE Gershenwald","year":"1998","unstructured":"Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol. 1998;16:2253\u201360.","journal-title":"J Clin Oncol."},{"key":"11251_CR40","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2001.19.11.2851","volume":"19","author":"KM McMasters","year":"2001","unstructured":"McMasters KM, Reintgen DS, Ross MI, et al. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol. 2001;19:2851\u20135.","journal-title":"J Clin Oncol."},{"key":"11251_CR41","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.jpedsurg.2016.02.067","volume":"51","author":"J Kim","year":"2016","unstructured":"Kim J, Sun Z, Gulack BC, et al. Sentinel lymph node biopsy is a prognostic measure in pediatric melanoma. J Pediatr Surg. 2016;51:986\u201390.","journal-title":"J Pediatr Surg."},{"key":"11251_CR42","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jso.24088","volume":"113","author":"MP Doepker","year":"2016","unstructured":"Doepker MP, Thompson ZJ, Harb JN, et al. Dermal melanoma: a report on prognosis, outcomes, and the utility of sentinel lymph node biopsy. J Surg Oncol. 2016;113:98\u2013102.","journal-title":"J Surg Oncol."},{"key":"11251_CR43","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2013.50.1114","volume":"31","author":"D Han","year":"2013","unstructured":"Han D, Zager JS, Shyr Y, et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol. 2013;31:4387\u201393.","journal-title":"J Clin Oncol."},{"key":"11251_CR44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1245\/ASO.2004.03.044","volume":"11","author":"VK Sondak","year":"2004","unstructured":"Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11:247\u201358.","journal-title":"Ann Surg Oncol."},{"key":"11251_CR45","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.amjsurg.2010.01.019","volume":"199","author":"MC Ellis","year":"2010","unstructured":"Ellis MC, Weerasinghe R, Corless CL, Vetto JT. Sentinel lymph node staging of cutaneous melanoma: predictors and outcomes. Am J Surg. 2010;199:663\u20138.","journal-title":"Am J Surg."},{"key":"11251_CR46","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1245\/s10434-011-1826-9","volume":"18","author":"RL White Jr","year":"2011","unstructured":"White RL Jr, Ayers GD, Stell VH, et al. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol. 2011;18:3593\u2013600.","journal-title":"Ann Surg Oncol."},{"key":"11251_CR47","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1245\/s10434-018-7006-4","volume":"26","author":"GC Karakousis","year":"2019","unstructured":"Karakousis GC, Gimotty PA, Leong SP, et al. Microsatellitosis in patients with melanoma. Ann Surg Oncol. 2019;26:33\u201341.","journal-title":"Ann Surg Oncol."},{"key":"11251_CR48","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/jso.20084","volume":"86","author":"KM McMasters","year":"2004","unstructured":"McMasters KM, Noyes RD, Reintgen DS, et al. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004;86:212\u201323.","journal-title":"J Surg Oncol."},{"key":"11251_CR49","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1002\/cam4.922","volume":"5","author":"JC Rubinstein","year":"2016","unstructured":"Rubinstein JC, Han G, Jackson L, et al. Regression in thin melanoma is associated with nodal recurrence after a negative sentinel node biopsy. Cancer Med. 2016;5:2832\u201340.","journal-title":"Cancer Med."},{"key":"11251_CR50","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.19.01902","volume":"38","author":"A Maurichi","year":"2020","unstructured":"Maurichi A, Miceli R, Eriksson H, et al. Factors affecting sentinel node metastasis in thin (T1) cutaneous melanomas: development and external validation of a predictive nomogram. J Clin Oncol. 2020;38:1591\u2013601.","journal-title":"J Clin Oncol."},{"key":"11251_CR51","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1067::AID-CNCR9>3.0.CO;2-T","volume":"85","author":"D Massi","year":"1999","unstructured":"Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Thin cutaneous malignant melanomas (\u22641.5 mm): identification of risk factors indicative of progression. Cancer. 1999;85:1067\u201376.","journal-title":"Cancer."},{"key":"11251_CR52","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.5858\/133.10.1560","volume":"133","author":"DP Frishberg","year":"2009","unstructured":"Frishberg DP, Balch C, Balzer BL, et al. Protocol for the examination of specimens from patients with melanoma of the skin. Arch Pathol Lab Med. 2009;133:1560\u20137.","journal-title":"Arch Pathol Lab Med."},{"key":"11251_CR53","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1001\/archderm.1987.01660340088026","volume":"123","author":"SG Ronan","year":"1987","unstructured":"Ronan SG, Eng AM, Briele HA, Shioura NN, Das Gupta TK. Thin malignant melanomas with regression and metastases. Arch Dermatol. 1987;123:1326\u201330.","journal-title":"Arch Dermatol."},{"key":"11251_CR54","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00000637-199201000-00023","volume":"28","author":"CL Slingluff Jr","year":"1992","unstructured":"Slingluff CL Jr, Seigler HF. \u201cThin\u201d malignant melanoma: risk factors and clinical management. Ann Plast Surg. 1992;28:89\u201394.","journal-title":"Ann Plast Surg."},{"key":"11251_CR55","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1046\/j.1365-2133.2003.05502.x","volume":"149","author":"J Olah","year":"2003","unstructured":"Olah J, Gyulai R, Korom I, Varga E, Dobozy A. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. Br J Dermatol. 2003;149:662\u20133.","journal-title":"Br J Dermatol."},{"key":"11251_CR56","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/CMR.0b013e32834dd003","volume":"22","author":"V Traves","year":"2012","unstructured":"Traves V, Botella-Estrada R, Requena C, Nagore E. Regression does not significantly underestimate melanoma thickness. Melanoma Res. 2012;22:96\u20138.","journal-title":"Melanoma Res."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-11251-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-021-11251-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-021-11251-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,7]],"date-time":"2022-04-07T14:19:39Z","timestamp":1649341179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-021-11251-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,21]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["11251"],"URL":"https:\/\/doi.org\/10.1245\/s10434-021-11251-z","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,21]]},"assertion":[{"value":"17 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Jonathan S. Zager received research funding from Amgen, Castle Biosciences, Delcath Systems, Novartis, Provectus, and Philogen; served on the medical advisory board for Delcath Systems, the speakers\u2019 bureau for Sun Pharma, and Pfizer; and is a consultant for Merck, Sanofi\/Regeneron, Amgen, and Castle Biosciences. John T. Vetto is a speaker for Castle Biosciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}